WO2012053985A1 - Synthèse améliorée d'un produit biosynthétique par assemblage ordonné d'enzymes biosynthétiques guidées par la matrice de motif de séquence nucléotidique - Google Patents

Synthèse améliorée d'un produit biosynthétique par assemblage ordonné d'enzymes biosynthétiques guidées par la matrice de motif de séquence nucléotidique Download PDF

Info

Publication number
WO2012053985A1
WO2012053985A1 PCT/SI2010/000058 SI2010000058W WO2012053985A1 WO 2012053985 A1 WO2012053985 A1 WO 2012053985A1 SI 2010000058 W SI2010000058 W SI 2010000058W WO 2012053985 A1 WO2012053985 A1 WO 2012053985A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
program
biosynthetic pathway
acid sequence
sequence
Prior art date
Application number
PCT/SI2010/000058
Other languages
English (en)
Inventor
Roman Jerala
Monika Avbelj
Mojca BENČINA
Jerneja Mori
Rok Gaber
Tomaž KOPRIVNJAK
Gregor Anderluh
Irena Vovk
Tina Lebar
Jernej TURNŠEK
Tina Ilc
Nejc TOMŠIC
Tjaša STOŠICKI
Matej ŽNIDARIČ
Jure Bordon
Mattia Petroni
Vesna Glavnik
Original Assignee
Kemijski inštitut
EN-FIST center odličnosti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemijski inštitut, EN-FIST center odličnosti filed Critical Kemijski inštitut
Priority to PCT/SI2010/000058 priority Critical patent/WO2012053985A1/fr
Priority to ATA9496/2010A priority patent/AT512453B1/de
Publication of WO2012053985A1 publication Critical patent/WO2012053985A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Definitions

  • the field of invention is an improved product synthesis achieved by the ordered assembly of chimeric proteins, the said chimeric proteins composed of biosynthetic enzymes or other functional polypeptides linked to nucleic acid binding factors whereas the ordered assembly of chimeirc proteins is based on binding to nucleic acid recognition motifs on the program nucleic acid sequence.
  • Invention is a biotechnological invention.
  • biosynthetic pathways composed of several enzymes and other proteins are engineered to achieve high yield of desired biosynthetic products. Improving the efficiency of biosynthetic pathways to yield more reaction product faster has been of great interest. Various strategies for optimization have been undertaken so far.
  • yield of end product of a biosynthetic reaction has been improved by (i) increasing pool of available substrate and / or overexpression of the enzymes of the limiting biosynthetic steps; (ii) introducing heterologous enzymes with preferred kinetic characteristics; (iii) blocking branching of biosynthetic pathway, (iv) compartmentalizing of biosynthetic pathways by directing enzymes of a particular biosynthetic pathway to a specific cell compartments or artificially made compartments (e.g. metabolosomes), or; (v) increasing the proximity of enzymes by assembling metabolic pathways on a protein scaffold (WO 2009/108774). While there are many advantages of protein based scaffold, this approach is limited by the number of available combinations of docking peptides and this approach does not offer a control of spatial distribution and orientation of biosynthetic enzymes to optimally support the biosynthetic pathway.
  • the protein scaffold has many disadvantages and limitations.
  • nucleic acid sequence motif template also named program nucleic acid sequence that guides the order of chimeric proteins, biosynthetic enzymes or other functional polypeptides linked to nucleic acid binding factors.
  • the inventors designed the chimeric polypeptides which are comprised of nucleic acid binding domain of a nucleic acid binding factor, and a biosynthetic enzyme or other functional polypeptide.
  • the said chimeric proteins bind to the target nucleic acid motif via a nucleic acid binding factor.
  • the program nucleic acid sequence determines the order of the target nucleic acid motifs and, hence, the sequence and spatial arrangement of biosynthetic enzymes or other functional polypeptides.
  • Such ordered biosynthetic pathway of chimeric biosynthetic enzymes or other functional polypeptides guided by the program nucleic acid sequence increases yield of biosynthetic product of such pathway in comparison to the protein scaffold, which simply clusters the biosynthetic enzymes without of any specified order.
  • Use of program nucleic acid sequence to immobilize and guide the order of chimeric biosynthetic pathway enzymes or other functional polypeptides provides for one or more of the following: i) increases the efficiency of pathway flux, ii) optimizes metabolic flux through the pathway, iii) reduces metabolic burden on the host cell, iv) provides the possibility of alternative branching of metabolic pathways yielding novel products of biosynthetic process, v) allows reprogramming of the chimeric enzymes within the organism by introducing different program nucleic acid.
  • the program nucleic acid sequence caries more than two target nucleic acid elements, these elements are specific ligands for nucleic acid binding factors.
  • the program nucleic acid sequence is present in a solution with chimeric proteins, the chimeric proteins bind to target elements within the program sequence form nucleic acid protein complex and facilitate formation of multi-protein complex.
  • chimeric proteins in such multi-protein complex is predictable due to the: i) positioning of target nucleic acid motifs is defined based on the nucleic acid sequence due to known three dimensional structure of nucleic acids, ii) because the order of nucleic acid motifs is predictable, it promotes ordered positioning of chimeric proteins; iii) such ordered positioning of chimeric proteins facilitates the order of biosynthetic reactions defined by the program nucleic acid sequence and therefore minimizes the time for diffusion of reaction intermediates between different biosynthetic reaction steps.
  • Inventors come to the conclusion that it is beneficial to have a large number of different nucleotide binding domains to assemble complex reaction pathways. For example there are 262144 different combinations of nucleotide motifs consisting of nine nucleotides, which can be recognized by different nucleotide binding domains allowing extremely high variability to assemble different biosynthetic pathways.
  • the present invention has several advantages over protein scaffolding.
  • the program nucleic acid sequence has no maturation problems and the ordered nucleotide binding motif can be selected at will.
  • Docldng of the anchoring nucleic acid binding factor to the target nucleic acid element is well characterized. Due to the close proximity of chimeric proteins bound to the program nucleic acid sequence other polypeptides that might redirect synthesis are spatially excluded from multi-protein complex.
  • binding of all components of the biosynthetic pathway proceeds under the same type of reaction conditions since all nucleic acid binding domains used for the construction of chimeric proteins can be based on the same protein fold and interact with the nucleotides using the same type of interactions as opposed to the protein scaffold, where different types of protein domain dimers have to be used, which can be correctly folded and interact optimally under different conditions.
  • the present invention has a an advantage that it can guide production of different reaction products depending on the sequence of the program nucleic acid that is introduced into production cells or reaction media, where the different program DNA differently assembles the biosynthetic pathway enzymes.
  • the present invention presents method of producing a compound by biosynthetic pathway and the method includes culturing a genetically modified host cell, which are modified to express chimeric proteins, biosynthetic pathway enzymes or other functional polypeptides linked to nucleic acid binding factors and program nucleic acid sequence which directs the ordered arrangement of chimeric proteins into a multi-protein biosynthetic complex.
  • the present invention refers to the processes that include at least three biosynthetic reaction steps up to approximately 100 steps. Three steps is the minimal size, where the order of reaction processes can differ and the ordered arrangement described in this invention has effect. Three steps can order for example reaction steps 1, 2, 3 as compared to the different orders 1, 3, 2 or 3, 1, 2.
  • the method includes mixing produced chimeric proteins, biosynthetic pathway enzymes or other functional polypeptides linked to nucleic acid binding factors produced in host cells and isolated from them and program nucleic acid sequence, which directs order of chimeric proteins into a multi-protein biosynthetic complex.
  • biosynthetic pathway is assembled in vitro, either in solution or with program DNA immobilized to another molecule or to the solid phase.
  • the in vitro assembled complex has to be incubated under conditions that support biosynthesis with the addition of required substrates and cofactors required for biosynthetic reaction or enzyme system that generates the required cofactors.
  • the present invention provides description of program nucleic acid design for in vivo and in vitro use. It provides genetically modified host cells comprising a program nucleic acid sequence and nucleic acid sequence encoding chimeric proteins, biosynthetic enzymes or other functional polypeptides covalently linked to anchoring nucleic acid binding factor that bind to specific target nucleic acid elements coded in the program nucleic acid sequence.
  • the present invention provides nucleic acids comprising program nucleic acid sequence for use in a method for improving yield of biosynthetic products.
  • the present invention enables design of bioprocesses towards specific end-products by excluding other polypeptides that might redirect synthesis to undesired products, due to the close proximity of functional groups of chimeric protein - bound to program nucleic acid.
  • the invention refers to genetically engineered host cells expressing chimeric proteins and/or replicating program nucleic acid sequence.
  • the invention also refers to the method which is used for producing a compound of any biosynthetic pathway that requires close proximity of biosynthetic enzymes to synthesize named compound.
  • the invention also refers to the processes such as information processing, chemical degradation, signaling, bio-sensing.
  • Figure 1 Schematic overview of benefits in using program nucleic acid sequence.
  • Figure 2. Effect of spacer sequence between target nucleic acid elements/motifs.
  • DNA was captured at the beginning of the cycle and the chimeric proteins were injected for 1 minute one after another in 2 different sequences: solid line: Znf azz, Znf_Blues, Znf_Zif268, ZnfJPBSII, Znf_HivC and Znf_Glil; dashed line: Znf_Glil, Znf_PBSII, Znf_HivC, Znfjazz, ZnfJBlues and Znf_Zif268.
  • the binding of all chimeric proteins in sequence showed that the binding of chimeric proteins was weaker if Znf_Glil was injected as the first one.
  • Figure 5 In vitro binding of nucleic acid binding factors on a program nucleic acid sequence. Binding of individual nucleic acid binding factors, Znf_Jazz, ZnfJBlues, Znf_Zif268, ZnfJPBSII, Znf jffivC and Znf _Glil was determined by mobility shift assay on agarose gel. Arrows indicate position of protein-DNA complex.
  • FIG.6 In vivo reconstitution of two non-functional Split-GFPs linked to nucleic acid binding factors in the presence of program nucleic acid sequence.
  • Plasmids, 75 ng each, carrying split YFP chimeric proteins (His_tag-Znf_PBSII_linker peptide-nYFP and cYFP-linker peptide-Znf_Zif268-linker peptide-His_tag) were cotransfected with 350 ng plasmid encoding program nucleic acid (Program SPR, split, FRET; Table 1). YFP emission signal at 529 nm was measured after excitation at 513 nm under a confocal microscope.
  • FIG. 7 In vitro reconstitution of two non-functional Split-GFPs linked to nucleic acid binding factors in the presence of program nucleic acid sequence. Lysates of HE 293 cell transfected with plasmids encoding either His_tag-Znf_Glil -linker peptide-nCFP and cCFP- linker peptide-Znf _HIVC-His_tag or HisJag-Znf PBSIIJinker peptide-nYFP and cYFP- linker peptide-Znf_Zif268 -linker peptide-His_tag were mixed with 50 ⁇ g of program nucleic acid (Program SPR, split, FRET; Table 1). After 18h incubation at 4°C , fluorescent spectra for CFP and YFP were obtained. Emission peaks are indicated with arrows.
  • FIG. 8 In vivo reconstitution of two pairs of split fluorescence proteins (Split CFP and split YFP) determined with FRET method.
  • HEK293 cells were cotransfected with plasmids encoding His_tag-Znf_Glil -linker peptide-nCFP, cCFP-linker peptide-Znf_HIVC-His_tag, His_tag-Znf_PBSII_linker peptide-nYFP, cYFP-linker peptide-Znf_Zif268-linker peptide- His_tag and plasmid encoding program nucleic acid (Program SPR, split, FRET; Table 1). [A.
  • Figure 9 Biosynthesis of violacein in the presence of program nucleic acid. Overnight cultures of E. coli containing plasmids encoding chimeric proteins Znf_Blues-linker peptide- vioA, Znf_Zif268-linker peptide-vioB, ZnfJPBSII-linker peptide-vioE, Znf_HivC-linker peptide- ioD, Znf_Glil -linker peptide-vioC (See Table 1) with or without plasmid encoding program nucleic acid (See Table 1, program biosynthesis (123456) or program biosynthesis (341256)).
  • the amount of violacein was quantified at 17.5 h after extraction and analysis by TLC.
  • the amount of violacein produced in the presence of program nucleic acid was much higher than when program nucleic acid (program biosynthesis 2341256) or no program nucleic acid was present in E. coli.
  • program /nucleic acid/ sequence refers to nucleic acid, which contains target nucleic acid sequences of any length and any number recognized by nucleic acid binding factors. These target nucleic acid sequences are separated with spacer nucleic acid sequences of any length.
  • the program nucleic acid sequence could be used as such or inserted into suitable vector to be inserted and amplified in host cell.
  • target /nucleic acid/ sequence refers to nucleic acid sequence of any length that is substrate for binding factor.
  • nucleic acid/ binding factor refers to any molecule with ability to bind nucleic acid molecule.
  • the binding factor could be of natural origin or artificially designed whole protein or only a segment with characteristic to bind to nucleic acid in sequence specific manner.
  • nucleic acid binding element is used as a carrier for enzyme included into biosynthetic pathway or any other functional polypeptide.
  • Nucleic acid binding molecule is connected with enzyme molecule via chemical bond. This is achieved via linker peptide.
  • Nucleic acid binding element binds to one or more specific sites on program nucleic acid sequence and assure high local concentration and proper spatial positioning of enzymes included into biosynthetic pathway.
  • spacer /nucleic acid/ sequence refers to nucleic acid sequence of any length that separates target nucleic acid sequences.
  • nucleic acids refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides includes but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer with phospho-tioate back bonds, comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non- natural, or derivatized nucleotide bases.
  • polypeptide refers to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically, or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.
  • functional polypeptide refers to a polymeric form of amino acids of any length, which expresses a function of any kind such as formation of structure, directing to a specific location, targeting organelles, facilitating and executing chemical reaction, binding to other functional polypeptide.
  • biosynthetic pathway enzyme refers to a polymeric form of amino acids of any length, which expresses a function of any kind such as formation of new chemical bond.
  • chimeric protein used herein, has a general meaning and in the description refers to a polymeric form of amino acids of any length, composed of more than one protein /domain/segment, optionally linked to each other with linker of any length preferentially containing from one to 40 amino acids and at least one protein /domain /segment is nucleotide binding factor, whole or binding domain and the other is biosynthetic pathway enzyme or other functional polypeptide, whole or activity domain.
  • heterologous refers to in the context of a genetically modified host cell, refers to a polypeptide wherein at least one of the following is true: (a) the polypeptide is foreign ("exogenous") to (i.e., not naturally found in) the host cell; (b) the polypeptide is naturally found in (e.g., is "endogenous to") a given host microorganism or host cell but is either produced in an unnatural (e.g., greater than expected or greater than naturally found) amount in the cell, or differs in nucleotide sequence from the endogenous nucleotide sequence such that the same encoded protein (having the same or substantially the same amino acid sequence) as found endogenously is produced in an unnatural (e.g., greater than expected or greater than naturally found) amount in the cell.
  • homologous refers to proteins or nucleic acid with well preserved amino acid or nucleotide sequences, preferably with at least 50% conservation, with a minimum of 20% conservation, determined by protein or nucleic acid alignment techniques, known to experts in the field. Homologous proteins are characterized by performing the same function in the cell. Homologous nucleic acids are coding for homologous proteins.
  • nucleic acid means that a particular nucleic acid (DNA or RNA) is the product of various combinations of cloning, restriction, and/or ligation steps resulting in a construct having a structural coding or non-coding sequence distinguishable from endogenous nucleic acids found in natural systems.
  • DNA sequences encoding the structural coding sequence can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of synthetic oligonucleotides, to provide a synthetic nucleic acid which is capable of being expressed from a recombinant transcriptional unit contained in a cell or in a cell-free transcription and translation system.
  • sequences can be provided in the form of an open reading frame uninterrupted by internal non- translated sequences, or introns, which are typically present in eukaryotic genes.
  • Genomic DNA comprising the relevant sequences can also be used in the formation of a recombinant gene or transcriptional unit.
  • Sequences of non- translated DNA may be present 5' or 3' from the open reading frame, where such sequences do not interfere with manipulation or expression of the coding regions, and may indeed act to modulate production of a desired product by various mechanisms (see “DNA regulatory sequences", below).
  • host cell denotes an in vivo or in vitro eukaryotic cell, a prokaryotic cell, or a cell from a multicellular organism (e.g., a cell line) cultured as a unicellular entity, which eukaryotic or prokaryotic cells can be, or have been, used as recipients for a nucleic acid (e.g., an expression vector that comprises a nucleotide sequence encoding one or more biosynthetic pathway gene products such as mevalonate pathway gene products), and include the progeny of the original cell which has been genetically modified by the nucleic acid.
  • a nucleic acid e.g., an expression vector that comprises a nucleotide sequence encoding one or more biosynthetic pathway gene products such as mevalonate pathway gene products
  • a “genetically modified host cell” (also referred to as a “recombinant host cell”) is a host cell into which has been introduced a heterologous nucleic acid, e.g., an expression vector.
  • a prokaryotic host cell is a genetically modified prokaryotic host cell (e.g., a bacterium), by virtue of introduction into a suitable prokaryotic host cell of a heterologous nucleic acid, e.g., an exogenous nucleic acid that is foreign to (not normally found in nature in) the prokaryotic host cell, or a recombinant nucleic acid that is not normally found in the prokaryotic host cell; and a eukaryotic host cell is a genetically modified eukaryotic host cell, by virtue of introduction into a suitable eukaryotic host cell of a heterologous nucleic acid, e.g., an exogenous nucleic acid that is foreign to the eukaryotic host cell, or a recombinant nucleic acid that is not normally found in the eukaryotic host cell.
  • a suitable prokaryotic host cell of a heterologous nucleic acid e.g., an exogenous nucle
  • biosynthetic pathway refers to sequence of enzymatic or other reactions by which one compound is converted to another by making new covalent bonds in organisms or in vitro.
  • in vitro refers to a procedure which is preformed not in a living organism or cell but in controlled environment.
  • linker peptide refers to shorter amino acid sequences, whose role could be only to separate the individual domains of the fusion protein.
  • the role of the linker peptide in the fusion protein may also be the introduction of the splitting site or for posttranslational modifications, including the introduction of sites for improved processing of antigens.
  • the length of the linker peptide is not restricted; however, it is usually up to 30 amino acids long.
  • the heterologous nucleic acid is inserted into expression vector.
  • Suitable vectors include, but are not limited to: plasmids, viral vectors, and others.
  • Expression vectors, compatible with host organism cells are well known to experts in the field and contain appropriate control elements for transcription and translation of nucleic acids.
  • the expression vector includes an antibiotic resistance cassette, a sequence for a chimeric protein under suitable promoter for guiding expression in host cells, polyadenylation signal and transcriptional terminator.
  • the present invention provides method of producing a product or a precursor of a biosynthetic pathway in a genetically engineered host cell or in vitro.
  • the method generally involves culturing the genetically engineered host cell under suitable conditions, under which genetically engineered host comprises: a) nucleic acids comprising nucleotide sequences encoding at least three or more binding factors linked to biosynthetic pathway enzymes or other functional polypeptides, and b) a nucleic acid comprising one or more program nucleic acid sequences.
  • the method generally involves formation of a product in vitro.
  • In vitro method comprises: a) at least three or more binding factors which are linked to a chimeric biosynthetic pathway enzymes or other functional polypeptides, and b) a nucleic acid comprising one or more program nucleic acid sequences, c) a substrate for the first enzyme and cofactors for enzymes are provided to the mixture.
  • a binding factor binds to the target nucleic acid element within the program nucleic acid sequence with sufficient association, providing association of chimeric biosynthetic pathway functional polypeptides with program nucleic acid sequence.
  • the association of the chimeric biosyntlietic pathway functional polypeptides with the program nucleic acid sequence is of sufficient affinity that the chimeric biosynthetic pathway enzymes or other functional polypeptides are immobilized on a program nucleic acids sequence.
  • the program nucleic acid sequence dictates the order of adjacent binding factors and therefore the sequential order of adjacent chimeric enzymes or other functional polypeptides.
  • the order of target target nucleic acid element with bound functional polypeptides can be arranged in the same order as they act in a particular biosynthetic reaction.
  • the order of adjacent target nucleic acid element with corresponding functional polypeptides can be changed by changing the sequence of adjacent target sequences within program nu cleic acid sequence, thereby providing an alternative order of adjacent biosynthetic enzymes or other functional polypeptides.
  • the host cell is cultured in such a way that a substrate for the first enzyme is: a) present in the cell, b) provided to the cell extracellularly.
  • the biosynthetic pathway enzymes are synthesised in the cell and convert the substrate into a product, b) the biosynthetic enzymes are synthesized in the cell, released from the cell and the substrate is converted to a product extracellularly.
  • program nucleic acid sequence to immobilize biosynthetic pathway functional polypeptides provides for one or more of the following: increased efficiency of pathway and optimized metabolic flux reduced metabolic burden and concentration of potentially toxic free intermediates in the cytosol, enable alternative branching of the metabolic pathways yielding novel products of biosynthetic process.
  • Balance of enzyme activity levels is achieved through the use of program nucleic acid sequence.
  • the sequence of the nucleic acid program can be changed in such a way that includes multiple copies of target nucleic acid elements for chimeric polypeptides witch have lower activity towards conversion of substrate, resulting in higher copy number of the functional polypeptides with lower activity than the copy number of functional polypeptide with higher activity.
  • At least three chimeric biosynthetic pathway enzymes or other functional polypeptides are immobilized onto nucleic acid program.
  • the first chimeric functional enzyme or polypeptide produces a first product that is a substrate for the second chimeric enzyme or other functional polypeptide.
  • Chimeric proteins, biosynthetic pathway enzymes or other functional polypeptides are positioned in close proximity of another. In this way, the effective concentration of the first product is high and the second chimeric biosynthetic pathway enzyme can act efficiently on the first product.
  • a program nucleic acid sequence includes (from 5' to 3'), a) one copy of a target nucleic acid element for the first chimeric polypeptide of biosynthetic pathway enzyme or other functional polypeptide, b) one copy of a target nucleic acid element for the second chimeric biosynthetic pathway functional polypeptide, and c) one copy of a target nucleic acid element for the third chimeric biosynthetic pathway functional polypeptide.
  • a program nucleic acid sequence includes (from 5' to 3'), a) one copy of a target sequence for the first chimeric biosynthetic pathway functional polypeptide, and b) two or more (e.g. two three, four, or more) copies of a target nucleic acid element for the second chimeric biosynthetic pathway enzyme or other functional polypeptide.
  • a ratio of any given chimeric functional polypeptide in a biosynthetic pathway can be varied.
  • the ratio of a first chimeric biosynthetic pathway functional polypeptide to a second chimeric biosynthetic pathway functional polypeptide can vary from about 0.1 :10, to about 10:0.1 and the ratio of the first to the third chimeric protein from about 0.1 ;10, to about 10:0.1 etc.
  • At least three or more (e.g. four, five, six, seven, or more) chimeric biosynthetic pathway enzymes are immobilized on a nucleic acid program.
  • the first chimeric biosynthetic pathway enzyme produces a first product that is a substrate for the second product that is a substrate for the third product chimeric biosynthetic pathway enzyme:
  • the order and the copy number of chimeric biosynthetic pathway enzymes is dictated by the sequence of the target nucleic acid sequence for particular chimeric biosynthetic pathway enzyme in a nucleic acid program.
  • Program nucleic acid sequence is designed to organize biosynthetic pathway enzymes into a functional complex.
  • Program nucleic acid sequence comprises three or more target nucleic acid elements for binding of nucleic acid binding factors. Binding of a nucleic acid binding factors which is linked to a chimeric biosynthetic pathway enzyme, to the target nucleic acid element, provides for immobilization of enzyme on the program nucleic acid sequence.
  • Each target nucleic acid element has a corresponding nucleic acid binding partner in a chimeric biosynthetic pathway enzyme or a functional polypeptide.
  • a given target nucleic acid element can be immediately adjacent to another target nucleic acid element, or can be separated from an adjacent target nucleic acid element through a spacer nucleic acid sequence.
  • the program nucleic sequence can be introduced to a variety of different types of host cells in a different form.
  • Examples of a different form of program nucleic acid sequence are, but are not limited to, baculovirus vectors, bacteriophage vectors, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral vectors (for example, but not limited to, viral vectors based on vaccinia virus, poliovirus, adenovirus, adeno-associated virus, SV40, herpes simplex virus, and the like), PI based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and other vectors.
  • the program nucleic acid sequence can be introduced into variety of host cells also as a liner nucleic acid molecule. All these forms of program nucleic acid sequence can also be used in in vitro embodiments of this invention. If program nucleic acid sequence is at least partially composed of RNA it can be used per se, but DNA coding for program nucleic acid sequence can also be used. DNA coding for program nucleic acid sequence that is used in in vitro or in vivo embodiments of this invention can be found in different forms. For example but not limiting to any form mentioned above.
  • program nucleic acid sequence can be present in one or more copies. More copies of individual program nucleic acid sequence can provide for higher number of functional biosynthetic complexes constructed of immobilized chimeric biosynthetic pathway enzymes. Individual copies of program nucleic acid sequences can be present in one or more nucleic acid molecules. Thus, amplifying the number of individual nucleic acid molecules in the production system with one or more copies of program nucleic acid sequence also provides for higher number of total copies of program nucleic acid sequences in producing system.
  • bacterial host cell can be transformed with self replicating plasmid, or any other type of nucleic acid molecule carrying program nucleic acid sequence in one or more copies, thus providing for higher total number of program nucleic acid sequences in the production system.
  • Plasmid carrying one or more copies of program nucleic acid sequences can also be present in system in one or more copies (for example, but not limited to, high copy number plasmid can be used for transforming bacterial host cell). Higher number of plasmids in the production system with one or more copies of program nucleic acid sequences also provides for higher total number of program nucleic sequences in the production system.
  • bacterial host cell can be transformed with a nucleic acid sequence coding for single, double, partially double, multi or partially multi stranded RNA molecule.
  • the program nucleic acid sequence can be present in one or more copies on individual RNA molecule. More copies of program nucleic acid sequences on individual RNA molecule provide for higher total number of program nucleic acid sequences in the production system. Coding nucleic acid sequence for RNA molecule can also be present in the production system in one or more copies. Higher copy number of coding nucleic acid sequences for RNA molecule provides for higher number of RNA molecules in the production system and therefore also for higher total number of program nucleic acid sequences in the production system.
  • Total number of individual RNA molecules in the production system can also be regulated with promoters used for driving transcription of coding nucleic acid sequences into RNA molecules consisting of one or more copies of program nucleic acid sequences. Stronger promoters provide for higher number of RNA molecules in the production system, thus providing for higher total number of individual program nucleic acid sequences in system. The higher total number of program nucleic acid molecules provides for the higher number of functional biosynthetic complexes constructed of immobilized chimeric biosynthetic pathway enzymes.
  • a program nucleic acid sequence comprises at least three target nucleic acid sequences, thus, at least three corresponding nucleic acid binding elements in three chimeric biosynthetic pathway enzymes bind to program nucleic acid sequence.
  • a program nucleic acid sequence has one, two or more copies of each target nucleic acid element. Each target nucleic acid element can thus be present in one or more copies. The copies can be in tandem or separated by spacer nucleic acid sequence. The copies of target nucleic acid element can also be separated with one or more other target nucleic acid element, which can also be present in one or more copies.
  • target nucleic acid elements are present on a program nucleic acid sequence, these can be different, thus providing proper spatial organization or high local concentration for the two different chimeric biosynthetic pathway enzymes or other functional polypeptides. If only three target nucleic acid elements are present on a program nucleic acid sequence, these can also be the same kind thus providing proper spatial organization or high local concentration for three copies of same chimeric biosynthetic pathway enzymes.
  • Specific target nucleic acid element is defined by nucleotide sequence from 5' to 3' end of nucleic acid molecule.
  • the target nucleic acid sequence can also be reverse complement sequence of original target nucleic acid sequence. Same nucleic acid binding factor binds to the target nucleic acid element and to the reverse complement sequence of target nucleic acid sequence but in different orientation and on different site of program nucleic acid sequence.
  • target nucleic acid element instead of target nucleic acid element can be useful if two chimeric bio synthetic pathway enzymes or other functional polypeptides are too large to be immediately adjacent to each other, or for achieving different spatial orientation of two copies of the same chimeric biosynthetic pathway enzymes or other functional polypeptides on a program nucleic acid sequence.
  • Spacer nucleic acid element can be placed on a program nucleic acid sequence in between two target nucleic acid elements to acquire enough space for large chimeric biosynthetic pathway enzymes or other functional polypeptides which act in succession in biosynthetic pathway.
  • the spacer nucleic acid sequence can also provide for proper spatial orientation of two adjacent or nearby chimeric biosynthetic pathway enzymes or other functional polypeptides.
  • program nucleic acid sequence can be double stranded DNA sequence, which forms turning helix structure.
  • Individual program nucleic acid sequence has a general formula [((X or X')n Sp)]m where Xn is a target nucleic acid sequence, Xn' is a reverse complement of target nucleic acid sequence, S is an optional spacer nucleotide sequence of any length, m is a integer from 3 and above and represents a number of target nucleic acid sequences with optional spacer nucleic acid sequence in program nucleic acid, n is an indicator of type of target nucleic acid element (e.g. XI, X2 and so on) and represents different individual target nucleic acid elements, p is an indicator of type of spacer element (e.g. SI, S2 and so on) and represents different individual spacer elements.
  • Xn is a target nucleic acid sequence
  • Xn' is a reverse complement of target nucleic acid sequence
  • S is an optional spacer nucleotide sequence of any length
  • m is a integer from 3 and above and represents a number of target nu
  • target nucleic acid sequence in the program nucleic acid sequence can be of any length and depends on corresponding nucleic acid binding element.
  • three finger DNA binding zinc finger proteins can be used.
  • length of target nucleic acid sequences is usually but not always 9 or 10 nucleotides.
  • program nucleic acid sequence has the formula (X1)(S1)(X2)(S2)(X3)(S3)(X4), where XI is the first target nucleic acid sequence for binding of the first chimeric biosynthetic pathway enzyme; where X2 is the second target nucleic acid sequence for binding of the second chimeric biosynthetic pathway enzyme; where X3 is the third target nucleic acid sequence for binding of the third chimeric biosynthetic pathway enzyme; where X4 is the fourth target nucleic acid sequence for binding of the fourth chimeric biosynthetic pathway enzyme; where SI if present, is the first spacer nucleotide sequence that ensures proper spatial orientation of adjacent chimeric biosynthetic pathway enzymes; where S2, if present, is the second spacer nucleotide sequence that ensures proper spatial orientation of adjacent chimeric biosynthetic pathway enzymes; where S3, if present, is the third spacer nucleotide sequence that ensures proper spatial orientation of
  • program nucleic acid sequence has the formula (X1)(S1)(X2)(S1)(X2)(S1)(X3), where XI is the first target nucleic acid sequence for the binding of first chimeric biosynthetic pathway enzyme; where X2 is the second target nucleic acid sequence for binding of the second chimeric biosynthetic pathway enzyme and is repeated twice in succession; where X3 is the third target nucleic acid sequence for binding of the third chimeric biosynthetic pathway enzyme; SI if present is the spacer nucleotide sequence of same type in between every pair of target nucleic acid sequence.
  • Successively repeated target nucleotide sequences can provide for higher local concentration of a rate limiting chimeric biosynthetic pathway enzyme resulting in an increased efficiency of pathway flux.
  • Successively repeated target nucleotide sequences can also provide for increased dimerization (or multimerization if specific target nucleic acid sequence is repeated more than two times in succession) of dimeric (or multimeric) chimeric biosynthetic pathway enzyme.
  • Successively repeated target nucleotide sequences (in this case X2) can also provide for increased efficiency of pathway flux in chimeric biosynthetic enzyme pathways where one enzyme acts on substrate more than one time in succession.
  • program nucleic acid sequence has the formula (X1)(S1)(X2)(S2)(X1)(S3)(X3) where XI is the first target nucleic acid sequence for the binding of the first chimeric biosynthetic pathway enzyme, and is repeated once again in program nucleic acid sequence but not in direct succession; where X2 is the second target nucleic acid sequence for the binding of the second chimeric biosynthetic pathway enzyme; where X3 is the third target nucleic acid sequence for the binding of the third chimeric biosynthetic pathway enzyme; where SI if present, is the first spacer nucleotide sequence that ensures proper spatial orientation of adjacent chimeric biosynthetic pathway enzymes; where S2, if present, is the second spacer nucleotide sequence that ensures proper spatial orientation of adjacent chimeric biosynthetic pathway enzymes; where S3, if present, is the third spacer nucleotide sequence that ensures proper spatial orientation of adjacent chimeric biosyn
  • This program nucleic acid sequence can be used for improving efficiency of chimeric biosynthetic enzyme pathways, where one chimeric biosynthetic pathway enzyme (in this case chimeric biosynthetic pathway enzyme that binds XI target nucleotide sequence) acts more than once in a chimeric biosynthetic enzyme pathway but not in immediate succession.
  • one chimeric biosynthetic pathway enzyme in this case chimeric biosynthetic pathway enzyme that binds XI target nucleotide sequence
  • NABF nucleic acid binding factor
  • biosynthetic pathway enzyme or other functional polypeptide attached together via amino acid linker.
  • NABF are of natural origin or artificially designed, and could be isolated from any organism.
  • NABF is any polypeptide, domain, protein or segment of protein that binds to nucleic acid.
  • NABF is an independently folded protein domain that contains at least one motif that recognizes nucleic acid sequence. NABF interacts with nucleotides in a sequence- specific manner.
  • polypeptides with NABF include, but are not limited to: helix-turn-helix, zinc finger, leucine zipper, winged helix, winged helix turn helix, helix-loop- helix and HMG-box .
  • Polypeptides with basic-helix-loop-helix motif are classified in leucine zipper factors, helix- loop-helix factors, helix-loop-helix / leucine zipper factors, NF-1, RP-X,and, bHSH. They are characterized by two a-helices connected by a loop. Transcription factors that include this domain typically bind to a consensus sequence called E-box (palindromic sequence (CACGTG)) as dimers. bHLH transcription factors bind to non-palindromic sequences, which are often similar to the E-box.
  • NABF are selected from superclass of Zinc- coordinating DNA-binding domains (Zinc-Finger domain), which is divided into subclasses: Cys4 zinc finger of nuclear receptor type, diverse Cys4 zinc fingers, Cys2His2 zinc finger domains, Cys6 cysteine-zinc cluster, and, Zinc fingers of alternating composition.
  • Individual zinc finger domains typically occur as tandem repeats with two, three, or more fingers comprising the DNA-binding domain of the protein. These tandem arrays can bind in the major groove of DNA and are typically spaced at 3-bp intervals.
  • the a-helix of each domain (often called the "recognition helix") can make sequence-specific contacts with nucleotides of nucleic acids; residues from a single recognition helix can contact 4 or more nucleotides to yield an overlapping pattern of contacts with adjacent zinc fingers.
  • NABF are selected from helix-turn-helix superclass of nucleotide binding polypeptides which is classified into six classes: homeo domain, fork head / winged helix, heat shock factors, tryptophan clusters, and transcriptional enhancer factor (TEA) domain.
  • Helix-turn-helix is a major structural motif capable of binding DNA, where recognition and binding to DNA is done by the two a helices, one occupying the N-terminal end of the motif, the other at the C-terminus.
  • Beta-Scaffold Factors with Minor Groove Contacts is the fourth superclass that is divided into more classes: RHR (Rel homology region), STAT, p53, MADS box, beta-Barrel alpha- helix transcription factors, TATA binding proteins, heteromeric CCAAT factors, grainyhead, Cold-shock domain factors and Runt.
  • transcription factors that bind to specific nucleotide sequence such as mutated restriction enzymes without restriction activity but with sequence recognition ability are also important .
  • the invention refers but is not limited to, polypeptides with Zinc-Finger domain, that form a small, independently folded zinc containing mini domain that recognizes specific nucleic acid sequence.
  • Zinc-Finger domains typically occur as tandem repeats with at least two, three, or more fingers comprising the DNA-binding domain of the protein. Each finger recognizes and binds to 3 base-pair subsites. Specific binding is mediated by amino acids of mini domain of Zinc-Finger on position 1, 2, 3 and 6 relative to the start of the alpha-helix.
  • modular or combinatorial approach we can multiply repeated mini domains and achieve chemical distinctiveness through variations in certain key amino acid residues.
  • fingers with different triplet specificities are combined to give the specific recognition of longer nucleic acid sequences.
  • With combining at least two or more Zinc-Finger domains we can minimize non-specific binding on nucleic acids present in host organisms and increase the specificity of Zinc-Finger containing polypeptides binding to the program nucleic acid.
  • Zinc-Finger-binding motifs are stable structures that rarely undergo conformational changes upon binding to their target.
  • functional polypeptide domain has been linked to at least one linker sequence that is covalently bound to biosynthetic pathway enzyme of interest.
  • Linker sequence determines the biosynthetic pathway enzyme or other functional polypeptide position with respect to Zinc-Finger binding domain and the adjacent biosynthetic pathway enzyme or other functional polypeptide.
  • Linker sequence can vary in length and amino acid sequence, and ensures that the covalently bound enzyme can form appropriate tertiary structure and thus retains the biological function.
  • the number of chimeric biosynthetic pathway enzymes or other functional polypeptides attached to NABF could be, but are not limited to three, four, five or more, and could be different from the number of individual target nucleic acid elements on a program nucleic acid sequence.
  • the number of chimeric biosynthetic pathway enzymes or other functional polypeptides attached to NABF binding factors depends on the number of steps in a biosynthetic pathway. If the biosynthetic pathway requires three, four, five different enzymes or other functional polypeptides to convert substrate to product or precursor at least three, four, five different binding elements, respectively, will be included into program nucleic acid sequence in a defined order.
  • the nucleic acid program which contains several repeats of individual targets element are also included in this invention.
  • RNA molecules can be used as a program nucleic acid sequences.
  • nucleic acids binding factors that recognize specific RNA sequences instead of specific DNA sequences should be used.
  • These can be, but are not limited to: RNA recognition motif (REM, also known as RED or the RNP motif), heterogeneous nuclear RNP K-homology domain (KH domain), zinc finger domains (best characterized RNA binding zinc finger domains are those of CCHH and CCCH type, but other types can also be used) and Pumilio (Puf) domains.
  • REM RNA recognition motif
  • KH domain heterogeneous nuclear RNP K-homology domain
  • zinc finger domains best characterized RNA binding zinc finger domains are those of CCHH and CCCH type, but other types can also be used
  • Pumilio (Puf) domains Pumilio
  • RNA binding domains that recognizes specific secondary structures on RNA molecules could also be used as nucleic acid binding factors (for example but not limited to SI domains) most suitable are sequence specific RNA binding domains (for example but not limited to zinc finger RNA binding domains).
  • sequence specific RNA binding domains for example but not limited to zinc finger RNA binding domains.
  • Inventors prefer usage of RNA binding domains that recognizes specific double stranded RNA sequences, because proper spatial orientation can be assured with them. Methods for designing sequence specific double stranded R A binding zinc fingers are described in literature.
  • the present invention refers to a method for increasing yield of production of biosynthetic products.
  • This method combines: (i) program nucleic acid sequence; and (ii) chimeric proteins of biosynthetic pathway enzymes or other functional polypeptides with NABF. All required components (i) and (ii) could be mixed (i) in vitro, in a solution with the presence of substrates and cofactors for the biosynthetic pathway enzymes, or, (ii) the components can be inserted and expressed in host cells in-vivo.
  • biosynthetic pathway is referred to any cascade of enzymes forming a new chemical bond to the substrate in the defined order, e.g. naturally occurring or artificially designed.
  • Artificial biosynthetic pathway refers to production of a product not known in nature. Artificial biosynthetic pathway also refers to production of a product known in nature but the enzymes of the biosynthetic pathway are not from the same organism or are obtained with genetic manipulations.
  • the invention refers to biosynthetic pathway, to any coupled enzymatic reaction that has to be performed sequentially with three or more enzymes.
  • the biosynthetic pathway (flux, efficiency) could be measured by determining the concentration of precursors and end products by the appropriate methods known to the experts in the field.
  • the invention refers to any biosynthetic pathway including, but not limited to:
  • secondary metabolic pathways such as, but not limited to, synthesis of secondary metabolites with biological activities, and pharmacological properties (polyketides), unusual peptides, hormones, terpenoids (carotenoids, %), pigments (violacein, melanin, %) etc.
  • Carotenoids belong to the category of tetraterpenoids. Astaxanthin, zeaxanthin and canthaxanthin are derived from ⁇ -carotene and their synthesis is mediated by carotenoid biosynthetic enzymes crtE, crtB, crti, crtY, crtO, crtZ, where the order and participation of enzymes leads to different products.
  • biosynthetic pathway that includes crtE, crtB, crti, crtY, crtO, crtZ leads to the synthesis of astxanthin, crtE, crtB, crti, crtY, crtZ leads to the synthesis of zeaxanthin, and crtL-E, crtB, crti, crtY, crtO to the synthesis of cantaxanthin, respectively.
  • VioA is an FAD dependent L-Trp oxidase, which generates IPA imine.
  • the latter is the substrate for VioB, a hemoprotein oxidase, which converts the IPA imine into a compound with an unknown chemical formula (compound X).
  • VioE is a recently discovered unique protein with no characterized homologues, and is a key enzyme in the violacein biosynthetic pathway - it acts by converting compound X to intermediates which can be taken over by VioD and VioC, FAD dependent monooxygenases which hydroxylate these compounds to form violacein.
  • Resveratrol (3,5,4'-transhydroxystilbene) is a plant-produced polyphenol.
  • Resveratrol biosynthetic pathway consists of four enzymes: phenylalanine ammonia lyase (PAL) and cinnamic acid 4-hydroxylase (C4H), which can be replaced by a single enzyme tyrosine ammonia lyase (TAL), 4-coumarate:CoA ligase (4CL) and stilbene synthase (STS).
  • the first two enzymes, PAL and C4H transform the amino acid phenylalanine into p-coumaric acid (4- coumaric acid).
  • the third enzyme, 4CL attaches p-coumaric acid to the pantetheine group of coenzyme-A (CoA) to produce 4-coumaroyl-CoA.
  • the final enzyme in the pathway, STS catalyzes the condensation of resveratrol from one molecule of 4-coumaroyl-CoA and three molecules of malonyl-CoA, which originate from fatty acid biosynthesis.
  • enzymes from particular biosynthetic pathways such as violacein, resveratrol and carotenoid biosynthetic pathway
  • NABFs increase the proximity of these chimeric proteins.
  • enzymes from particular biosynthetic pathways such as violacein, resveratrol and carotenoid biosynthetic pathway
  • the advantage of our invention is the ability to produce artificial compounds with desired characteristics.
  • Standard molecular biology methods are used in the invention that are generally known to experts in the field.
  • the invented proteins of the polypeptide material can be synthesized by expressing DNA coding for proteins in a suitable host organism.
  • the DNA coding for the proteins is inserted in an appropriate expression vector.
  • Suitable vectors include, but are not limited to: plasmids, viral vectors, etc.
  • Expression vectors, which are compatible with the host organism cells, are well known to the experts in the field and include the appropriate control elements for transcription and translation of nucleic acid sequence.
  • Expression vector may be prepared for expression in prokaryotic and eukaryotic cells.
  • prokaryotic cells are bacteria, primarily Escherichia coli. According to the invention, prokaryotic cells are used to get a sufficient quantity of nucleic acid.
  • Expression vector generally contains the operationally associated control elements which are operationally linked to the DNA of the invention, which codes for the protein. The control elements are selected in a way to trigger efficient and tissue-specific expression.
  • the promoter may be constitutive or inducible, depending on the desired pattern of expression.
  • the promoter may be of native or foreign origin (not represented in the cells, where it is used), and may be natural or synthetic. The promoter must be chosen in order to work in the target cells of the host organism.
  • initiation signals for the efficient translation of fusion protein are included, which comprises the ATG and the corresponding sequences.
  • the vector, used in the invention includes two or more reading frames, should the reading frames be operationally associated with control elements independently and the control elements should be the same or different, depending on the desired production of proteins.
  • the Designer enables the user to design DNA fragments and optimize expression for the desired hosts (e.g. E. coli) by organism specific codon optimization.
  • Genes were ordered from GENEART AG (Imretepark B32, D-93059 Regensburg), digested with restriction enzymes and cloned into the appropriate vector containing appropriate regulatory sequences, by the procedure known to the experts in the field.
  • DNA sequences for split fluorescence proteins were amplified by PGR using DNA sequence of fluorescence proteins as a template (accession number or reference needed).
  • Vectors used include commercial vectors pET, pBluescript, pCDNA, pSBlA2 (pSBlA2 http://partsregistrv.0rg/Part:pSB 1 A2) pSBlC3
  • DNA fragmentation with restriction enzymes DNA amplification using polymerase chain reaction-PCR, PCR ligation, DNA concentration detection, agarose gel electrophoresis, purification of DNA fragments from agarose gels, ligation of DNA fragments into a vector, transformation of chemically competent cells E. coli DH5a, isolation of plasmid DNA with commercially available kits, screening and selection
  • DNA segments were characterized by restriction analysis and sequencing.
  • DNA constructs and corresponding chimeric proteins are described in Table 1. All DNA constructs have start codon (ATG) before tag of histidines or coding region.
  • the constructs coding for chimeric proteins were cloned into pET19b vector for high-level expression or pSB4K5 and pSB4C5 for monitoring in vivo production of carotenoids and violacein, respectively.
  • the expression cassette includes in 5' to 3' direction the T7 promoter, multiple cloning site for fusion protein, and T7 terminator. These regulatory elements enable expression of protein in prokaryotic cell line E. coli carrying T7 R A polymerase.
  • DNA constructs were prepared by using methods of molecular biology that are basically described in any molecular biology handbook and known to experts. Plasmids, constructs and intermediate constructs were transformed with chemical transformation into bacterium E. coli DH5alfa or BL21 (DE3) pLysS.
  • Plasmids encoding open reading frames of fusion proteins in Table 1 were transformed with chemical transformation into competent E. coli BL21 (DE3) pLysS cells. Selected bacterial colonies grown on LB plates with selected antibiotic (ampicillin) were inoculated into 10 mL of LB broth supplemented with selected antibiotic. After several hours of growth at 37°C 10-100 ⁇ , of the culture were inoculated into 100 mL of selected growth media and left overnight shaking at 37°C. The overnight culture was diluted 20-50-times reaching the OD 6 oo of diluted culture between 0.1 and 0.2.
  • Precipitate cell membranes, inclusion bodies
  • supernatant were checked for expression of our constructs by SDS-PAGE and Western blot, using anti-His-tag antibodies as primary antibodies when necessary.
  • Designed fusion proteins were mainly present in insoluble part (inclusion bodies), which was composed of >80% of the chosen protein. Inclusion bodies were washed twice with lysis buffer, twice with 1 M urea in 10 mM Tris pH 8.0 and twice with 2 M urea in 10 mM Tris pH 8.0. Usually this treatment resulted in >95% of protein purity.
  • Purified inclusion bodies where dissolved in 8 M urea in 50 mM Tris pH 8.0.
  • Proteins were eluted with 8 M urea in 50 mM Tris pH 8.0 and 250 mM imidazole. Protein refolding was carried out by dialysis against buffer containing 50 mM Tris pH 8.0, 500 niM NaF, 500 ⁇ ZnS0 4 , 5 niM DTT, 0,005 % Tween and 10 % glycerol. Dialysis was carried out at least twice for 12 h at 4 °C with no mixing. Upon completion of the process the dialysate was carefully removed from the dialysis tubes and placed into centrifuge tubes. Protein that failed to refold precipitated and was separated from the refolded protein in the soluble phase via centrifugation at 10,000 rpm. Protein concentration was determined using spectrophotometer and Bradford protein assay and protein size determined by SDS-PAGE/commasie stain and Western blot analysis using anti- His antibodies.
  • Table 1 Composition of plasmids, prepared for invention demonstration.
  • Bacterial cultures carrying plasmid constructs listed in Table 1 were incubated in 10 ml LB broth supplemented with 5 ⁇ 1 IPTG (1M) (isopropyl- -D-thio-galactoside) and increasing concentrations of (0%, 0,0025%, 0,1% and 1%) L-arabinose at 37°C on a rotary shaker at 180 rpm for 18 hours.
  • Bacterial density was determined by optical density (OD600). The measurements of ⁇ -galactosidas activity were performed in an ELISA-reader, preheated on 28°C.
  • each culture was transferred to the wells of a 96-well microliter clear-bottom plate to which 100 ⁇ of Z-buffer with chloroform (Z-buffer: 0,06 M Na2HP04 x 7H20, 0,04 M NaH2P04 x H20, 0,1M C1, 0,001 M MgS04x7H20, pH 7; Z-buffer with chloroform: Z- buffer, 1% ⁇ -mercaptoethanol, 10% chloroform) was added.
  • Bacterial cells were lysed by addition of 50 ⁇ of Z-buffer with SDS (Z-buffer, 1,6 % SDS) followed by incubation for 10 min at 28°C. 50 ⁇ of 0.4 % ONPG solution in Z-buffer was added to each well and changes in OD 405 were measured for a period of 20 min at 30 sec intervals.
  • the reporter contains plasmid composed of a) lacZ under synthetic promoter containing a DNA binding site for the particular DNA binding protein tested and b) a corresponding DNA binding protein under arabionose promoter.
  • the successful binding of NABF to the synthetic promoter would prevent transcription of lacZ resulting in lower ⁇ - galactosidaze activity.
  • E. coli cultures containing plasmids for various NABF were grown overnight in LB medium supplemented with increasing concentrations of arabinose.
  • ⁇ - galactosidaze activity was measured as described in the text. In all constructs tested, the activity of ⁇ -galactosidaze decreased with increasing concentrations of arabinose suggesting that the NABF (Table 1) bind to the target nucleic acid element within the synthetic promoter in vivo ( Figure 3A). Furthermore, ⁇ -galactosidaze activity was unaffected in the presence of mismatching NABF and DNA target sequence (e.g. Blues target element - blues_0 was changed with PBSII target element PBSII_0, and HivC_0 target element was swapped with Gli__0 target element), reiterating the specificity of our testing system system (Figure 3B).
  • Blues target element - blues_0 was changed with PBSII target element PBSII_0
  • HivC_0 target element was swapped with Gli__0 target element
  • the analyte binding was observed by injection of different concentrations for 1 min following the dissociation which was monitored for 5 min.
  • the regeneration of surface was achieved with two 30 s injections of 50 mM NaOH and one 24 s injection of 0.5 % SDS. After that the new DNA was injected to obtain fresh binding surface.
  • CM5 Series S sensor chip CM5 (Ge Healthcare) was immobilized with 3000 RU of avidin via amine coupling using manufacturer's protocol.
  • the carboxymethylated surface of CM5 chip was activated using a 7 min injection pulse of 1 : 1 NHS:EDC.
  • Avidin in Na-acetate pH 5.5 was then injected in several short pulses to reach the response of 3000 RU.
  • the avidin was coupled only to second flowcell while first flowcell served as a reference surface to substract the nonspecific binding of analytes to dextran matrix on a sensor chip. Unreacted sites on the sensor surface were blocked with a 7 min injection pulse of 1 M ethanolamine (pH 8.5).
  • Figure 4A presents binding of program DNA than binding of chimeric protein containing Glil NABF and regeneration of support. Hybridization of DNA was performed by injection 0.5-2 ⁇ up to 300 s to get the final response of 300 RU. The analyte binding was observed by injecting different concentrations for 1 min following the 5 min dissociation. The regeneration was achieved with two 30 s injections of 50 mM NaOH and 24 s injection of 0.5 % SDS.
  • Leica TCS SP5 laser confocal microscope was used for detection of chimeric split fluorescent (e.g. NABF linked to nCFP, NABF linked to cCFP) proteins and FRET reconstitution on a nucleic acid program in vivo.
  • chimeric split fluorescent e.g. NABF linked to nCFP, NABF linked to cCFP
  • FRET reconstitution on a nucleic acid program in vivo.
  • Transfected HEK293 cells that were cultured overnight on 8-well microscope slide at 37°C were placed on top of objective lens carrying a droplet of immersion oil. Cells were excited at 433 nm for CFP and 515 nm for YFP.
  • FRET was detected according to the methodology provided by the manufacturer's software (FRET AB and FRET SE wizards within Leica LAS AF computer software).
  • HEK293 cells were transfected with mammalian expression vectors carrying split fluorescent fusion proteins under CMV promoter using jetPEITM tranfection reagent protocol and ultimately fixed with 4% paraformaldehyde.
  • Split fluorescent protein reconstitution as well as FRET effect were observed under confocal microscope (described under "Confocal microscopy").
  • CFP Znf_Glil -linker peptide-nCFP and cCFP-linker peptide- Znf_HivC
  • YFP Znf PBSII-linker peptide-nYFP and cYFP-linker peptide-Znf_Zif268) were reconstituted only in the presence of specific, but not random, program nucleic acid.
  • Split fluorescent proteins bind to adjacent target nucleotide sequences when plasmids carrying split fluorescent protein fusions are cotransfected with a plasmid carrying target program nucleic acid. As split fluorescent proteins cannot form a fully formed chromophore in vivo by accident, fluorescent signal comes as a consequence of split protein - zinc finger fusions bound to a DNA program nucleic acid sequence.
  • FIG. 6 shows in vivo reconstitution of two non-functional fluorphores (split-GFPs) linked to NABF only in the in the presence of program nucleic acid sequence (Figure 6A).
  • Plasmids, 75 ng each, carrying Znf_Glil -linker peptide-nCFP and cCFP -linker peptide- Znf fflVC were cotransfected with 350ng of program DNA into HEK293 cells. Cyan fluorescent protein emission signal was observed by exciting cells with 433 nm laser light ( Figure 6B).
  • Plasmids, 75 ng each, carrying split yellow fluorescent protein fusions (Znf_PBSII_linker peptide-nYFP and cYFP-linker peptide Znf_Zif268) were cotransfected with 350 ng program DNA.
  • YFP emission signal with a 529 nm peak was observed under a confocal microscope ( Figure 6C).
  • HEK293 cells were cotransfected with Znf _Glil -linker peptide-nCFP, cCFP-linker peptide-Znf_HivC and Znf_PBSII-linlcer peptide-nYFP, cYFP- linker peptide-Znf _Zif268 respectively.
  • Cells were lysed in 150 ⁇ 1 Promega Passive Lysis Buffer after 72 hours, when 5( ⁇ g of program nucleic acid was introduced. Functional fluorophore was observed after incubating cell lysates with DNA program for 18 h at 4°C using PerkinElmer LS55 Luminescence Spectrometer.
  • FRET efficiency FRET efficiency of four chimeric proteins, split GFPs linked to NABF in the presence of program DNA is presented in Table 2.
  • HE 293 cells were transfected with program DNA and Znf_Glil -linker peptide-nCFP, cCFP-linker peptide- Znf_HIVC, Znf_PBSII-linker peptide-nYFP, Znf cYFP- linker peptide-Znf_Zif268.
  • negative control cells were transfected with cytosolic CFP and YFP without DNA binding factors, and for positive control cells were transfected CFP linked to YFP via linker peptide
  • Table 2 FRET efficiency of four split GFPs each linked to different DNA binding factor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne un procédé de production d'un composé par une voie biosynthétique par la mise en culture d'une cellule hôte génétiquement modifiée, la cellule étant modifiée par un ou plusieurs acides nucléiques comprenant une séquence nucléotidique codant pour des protéines chimériques composées d'une enzyme d'une voie biosynthétique ou pour un autre polypeptide fonctionnel, et d'un facteur de liaison à un acide nucléique, et une séquence d'acide nucléique programmée qui contient des éléments cibles d'acide nucléique qui sont reconnus par ledit facteur de liaison à un acide nucléique provenant de la protéine chimérique, et dans lequel ladite séquence d'acide nucléique programmée permet un agencement des enzymes de la voie biosynthétique ou d'autres polypeptides fonctionnels le long de la séquence d'acide nucléique programmée, et ladite mise en culture permettant la synthèse desdites protéines chimériques dans les cellules hôtes génétiquement modifiées conduisant à une production dudit composé. L'invention concerne des cellules hôtes ayant une séquence d'acide nucléique programmée, des protéines chimériques exprimant la séquence d'acide nucléique. L'invention concerne également des procédés améliorant la synthèse de produits.
PCT/SI2010/000058 2010-10-22 2010-10-22 Synthèse améliorée d'un produit biosynthétique par assemblage ordonné d'enzymes biosynthétiques guidées par la matrice de motif de séquence nucléotidique WO2012053985A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/SI2010/000058 WO2012053985A1 (fr) 2010-10-22 2010-10-22 Synthèse améliorée d'un produit biosynthétique par assemblage ordonné d'enzymes biosynthétiques guidées par la matrice de motif de séquence nucléotidique
ATA9496/2010A AT512453B1 (de) 2010-10-22 2010-10-22 Verbesserte Synthese eines biosynthetischen Produkts mit einer angeordneten Zusammensetzung der biosynthetischen Enzyme auf einem Nukleotidsequenzmotiv

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SI2010/000058 WO2012053985A1 (fr) 2010-10-22 2010-10-22 Synthèse améliorée d'un produit biosynthétique par assemblage ordonné d'enzymes biosynthétiques guidées par la matrice de motif de séquence nucléotidique

Publications (1)

Publication Number Publication Date
WO2012053985A1 true WO2012053985A1 (fr) 2012-04-26

Family

ID=43769307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SI2010/000058 WO2012053985A1 (fr) 2010-10-22 2010-10-22 Synthèse améliorée d'un produit biosynthétique par assemblage ordonné d'enzymes biosynthétiques guidées par la matrice de motif de séquence nucléotidique

Country Status (2)

Country Link
AT (1) AT512453B1 (fr)
WO (1) WO2012053985A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130130347A1 (en) * 2011-10-06 2013-05-23 Cornell University Constructs and methods for the assembly of biological pathways
WO2017216300A1 (fr) * 2016-06-15 2017-12-21 Universite Claude Bernard Lyon 1 Vecteurs et banques de cellules pour une methode de criblage d'interaction proteine-proteine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056904A1 (fr) * 1997-06-12 1998-12-17 Rigel Pharmaceuticals, Inc. Complexes enzymatiques combinatoires
WO2002018617A2 (fr) * 2000-09-01 2002-03-07 E.I. Dupont De Nemours And Company Production de carotenoides a partir d'un substrat de carbone simple
WO2002050299A2 (fr) * 2000-12-20 2002-06-27 Stiftung Alfred-Wegener-Institut Für Polar- Und Meeresforschung Procede microbiologique de biosynthese des colorants naturels bleu-violets violaceine et desoxyviolaceine et leur utilisation
WO2003068917A2 (fr) * 2002-02-11 2003-08-21 E.I. Du Pont De Nemours And Company Fonctionnalisation des composes carotenoides
WO2006125000A2 (fr) * 2005-05-19 2006-11-23 E.I. Du Pont De Nemours And Company Procede de production du resveratrol dans un micro-organisme oleagineux de recombinaison
WO2009108774A2 (fr) 2008-02-28 2009-09-03 The Regents Of The University Of California Utilisation de structures synthétiques pour la production de produits de voie biosynthétique
WO2010003304A1 (fr) * 2008-07-11 2010-01-14 清华大学 Bactéries recombinées pour produire de la désoxyviolacéine et leurs utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056904A1 (fr) * 1997-06-12 1998-12-17 Rigel Pharmaceuticals, Inc. Complexes enzymatiques combinatoires
WO2002018617A2 (fr) * 2000-09-01 2002-03-07 E.I. Dupont De Nemours And Company Production de carotenoides a partir d'un substrat de carbone simple
WO2002050299A2 (fr) * 2000-12-20 2002-06-27 Stiftung Alfred-Wegener-Institut Für Polar- Und Meeresforschung Procede microbiologique de biosynthese des colorants naturels bleu-violets violaceine et desoxyviolaceine et leur utilisation
WO2003068917A2 (fr) * 2002-02-11 2003-08-21 E.I. Du Pont De Nemours And Company Fonctionnalisation des composes carotenoides
WO2006125000A2 (fr) * 2005-05-19 2006-11-23 E.I. Du Pont De Nemours And Company Procede de production du resveratrol dans un micro-organisme oleagineux de recombinaison
WO2009108774A2 (fr) 2008-02-28 2009-09-03 The Regents Of The University Of California Utilisation de structures synthétiques pour la production de produits de voie biosynthétique
WO2010003304A1 (fr) * 2008-07-11 2010-01-14 清华大学 Bactéries recombinées pour produire de la désoxyviolacéine et leurs utilisations
GB2473401A (en) * 2008-07-11 2011-03-09 Univ Tsinghua Recombinant bacteria for producing deoxyviolacein and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130130347A1 (en) * 2011-10-06 2013-05-23 Cornell University Constructs and methods for the assembly of biological pathways
US9322023B2 (en) * 2011-10-06 2016-04-26 Cornell University Constructs and methods for the assembly of biological pathways
WO2017216300A1 (fr) * 2016-06-15 2017-12-21 Universite Claude Bernard Lyon 1 Vecteurs et banques de cellules pour une methode de criblage d'interaction proteine-proteine
FR3052788A1 (fr) * 2016-06-15 2017-12-22 Univ Claude Bernard Lyon Vecteurs et banques de cellules pour une methode de criblage d'interaction proteine-proteine

Also Published As

Publication number Publication date
AT512453A2 (de) 2013-08-15
AT512453A5 (de) 2015-04-15
AT512453B1 (de) 2015-05-15

Similar Documents

Publication Publication Date Title
CA2583009C (fr) Conjugues de proteine utilisables en therapie, pour le diagnostic et en chromatographie
Luna-Vargas et al. Enabling high-throughput ligation-independent cloning and protein expression for the family of ubiquitin specific proteases
Öberg et al. Improving recombinant eukaryotic membrane protein yields in Pichia pastoris: the importance of codon optimization and clone selection
WO2016014501A1 (fr) Molécules de sortase et leurs utilisations
CN110172467B (zh) 一种利用嵌合设计方法构建正交的氨酰-tRNA合成酶/tRNA体系
CN108484764B (zh) 一种针对绿色荧光蛋白的纳米抗体及其编码序列
US20030138843A1 (en) Method for determining and modifying protein/peptide solubility
WO2012053985A1 (fr) Synthèse améliorée d'un produit biosynthétique par assemblage ordonné d'enzymes biosynthétiques guidées par la matrice de motif de séquence nucléotidique
JP5865002B2 (ja) 組換えプラスミドベクターおよびそれを用いたタンパク質の製造方法
US20160319287A1 (en) Atypical inteins
CN112813049A (zh) 用于活细胞rna标记的融合蛋白及应用
CN113652430B (zh) 一种光控rna代谢调控系统
Kalichuk et al. Affitins: ribosome display for selection of Aho7c-based affinity proteins
CN114057861B (zh) 一种靶向UBE2C的bio-PROTAC人工蛋白
EP3702495A1 (fr) Protéine de type anticorps
KR20220023985A (ko) 효율적인 피피알 단백질의 작제방법 및 그의 이용
Gibbs et al. Identification of functional residues in proteins by charged-to-alanine scanning mutagenesis
SI23510A (sl) Izboljšana sinteza produkta biosinteze z usmerjenim sestavljanjem biosintetskih encimov na motivu nukleotidnega zaporedja
Lawrence et al. Recombinant production and purification of the subunit c of chloroplast ATP synthase
JP7553993B1 (ja) 発光タンパク質
US8415146B2 (en) Vector and utilization of the same
CN112851765B (zh) 蛋白或肽与核酸共价连接的方法
US11214791B2 (en) Engineered FHA domains
Taschner et al. 4G cloning: rapid gene assembly for expression of multisubunit protein complexes in diverse hosts
Pavithran Mechanistic Insights into the Stabilisation of Gram Negative Bacterial Biofilms by HU And Cloning, Expression and Purification of IHF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784598

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 94962010

Country of ref document: AT

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10784598

Country of ref document: EP

Kind code of ref document: A1